GenMark Diagnostics announced that its initial public offering of 4,600,000 shares of its common stock has been priced at $6.00 per share. T
he shares are expected to begin trading today on the NASDAQ Global Market under the ticker symbol “GNMK.” In addition, GenMark has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares to cover over-allotments, if any.
Piper Jaffray & Co. is acting as sole book-running manager of the offering. The co-managers are William Blair & Company, L.L.C. and ThinkEquity LLC. A registration statement relating to the shares of GenMark’s common stock offered in the initial public offering has been declared effective by the Securities and Exchange Commission. The offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained by contacting Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, Attention: Prospectus Department, 800-754-4781. The final prospectus, when it is available, also may be obtained on the Securities and Exchange Commission’s Web site at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Source: GenMark Diagnostics